CA2805976C - Polypeptide immunosuppresseur et acides nucleiques - Google Patents

Polypeptide immunosuppresseur et acides nucleiques Download PDF

Info

Publication number: CA2805976C
Authority: CA; Canada
Prior art keywords: polypeptide; seq; sequence; amino acid; fusion protein
Prior art date: 2007-11-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA2805976A

Other languages

English (en)

Other versions

CA2805976A1 (fr

Inventor

Erik E. Karrer

Madan M. Paidhungat

Steven H. Bass

Margaret Neighbors

Juha Punnonen

Steven J. Chapin

Sridhar Viswanathan

Brent R. Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Astellas Pharma Inc

Original Assignee

Astellas Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-01

Filing date

2008-10-15

Publication date

2015-05-26

2008-10-15 Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc

2008-10-15 Priority claimed from CA2703263A external-priority patent/CA2703263C/fr

2009-05-07 Publication of CA2805976A1 publication Critical patent/CA2805976A1/fr

2015-05-26 Application granted granted Critical

2015-05-26 Publication of CA2805976C publication Critical patent/CA2805976C/fr

Status Expired - Fee Related legal-status Critical Current

2028-10-15 Anticipated expiration legal-status Critical

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 978
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 970
229920001184 polypeptide Polymers 0.000 title claims abstract description 969
150000007523 nucleic acids Chemical class 0.000 title claims abstract description 160
102000039446 nucleic acids Human genes 0.000 title claims abstract description 138
108020004707 nucleic acids Proteins 0.000 title claims abstract description 138
230000001506 immunosuppresive effect Effects 0.000 title abstract description 16
102000037865 fusion proteins Human genes 0.000 claims abstract description 392
108020001507 fusion proteins Proteins 0.000 claims abstract description 392
238000000034 method Methods 0.000 claims abstract description 121
239000013636 protein dimer Substances 0.000 claims abstract description 84
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims abstract description 33
125000000539 amino acid group Chemical group 0.000 claims description 193
230000028993 immune response Effects 0.000 claims description 174
238000004519 manufacturing process Methods 0.000 claims description 54
230000002401 inhibitory effect Effects 0.000 claims description 42
108091033319 polynucleotide Proteins 0.000 claims description 42
102000040430 polynucleotide Human genes 0.000 claims description 42
239000002157 polynucleotide Substances 0.000 claims description 42
208000026278 immune system disease Diseases 0.000 claims description 33
210000000056 organ Anatomy 0.000 claims description 33
238000011282 treatment Methods 0.000 claims description 28
230000000069 prophylactic effect Effects 0.000 claims description 26
239000013598 vector Substances 0.000 claims description 24
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 22
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 22
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 17
241000124008 Mammalia Species 0.000 claims description 16
102000054189 human CD80 Human genes 0.000 claims description 16
230000001225 therapeutic effect Effects 0.000 claims description 16
101000946850 Homo sapiens T-lymphocyte activation antigen CD86 Proteins 0.000 claims description 13
102000049849 human CD86 Human genes 0.000 claims description 13
239000003814 drug Substances 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 5
206010052779 Transplant rejections Diseases 0.000 claims description 4
239000001963 growth medium Substances 0.000 claims description 4
238000012258 culturing Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
239000000203 mixture Substances 0.000 abstract description 9
102000008203 CTLA-4 Antigen Human genes 0.000 abstract 2
108010021064 CTLA-4 Antigen Proteins 0.000 abstract 2
229940045513 CTLA4 antagonist Drugs 0.000 abstract 2
235000001014 amino acid Nutrition 0.000 description 188
238000009739 binding Methods 0.000 description 160
230000027455 binding Effects 0.000 description 155
125000003275 alpha amino acid group Chemical group 0.000 description 145
239000000539 dimer Substances 0.000 description 140
238000006467 substitution reaction Methods 0.000 description 105
210000004027 cell Anatomy 0.000 description 103
108090000623 proteins and genes Proteins 0.000 description 97
102000004169 proteins and genes Human genes 0.000 description 85
235000018102 proteins Nutrition 0.000 description 84
229940024606 amino acid Drugs 0.000 description 73
150000001413 amino acids Chemical class 0.000 description 72
241000282414 Homo sapiens Species 0.000 description 64
239000000178 monomer Substances 0.000 description 62
229940035567 orencia Drugs 0.000 description 60
210000001744 T-lymphocyte Anatomy 0.000 description 59
108010076504 Protein Sorting Signals Proteins 0.000 description 56
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 52
230000006052 T cell proliferation Effects 0.000 description 50
125000003729 nucleotide group Chemical group 0.000 description 48
230000006044 T cell activation Effects 0.000 description 43
239000002773 nucleotide Substances 0.000 description 40
101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 38
102000043321 human CTLA4 Human genes 0.000 description 37
238000001727 in vivo Methods 0.000 description 34
208000023275 Autoimmune disease Diseases 0.000 description 32
210000001519 tissue Anatomy 0.000 description 32
230000001419 dependent effect Effects 0.000 description 31
238000000338 in vitro Methods 0.000 description 30
239000012634 fragment Substances 0.000 description 29
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 27
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 27
238000004422 calculation algorithm Methods 0.000 description 27
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 27
201000010099 disease Diseases 0.000 description 26
208000035475 disorder Diseases 0.000 description 26
230000004913 activation Effects 0.000 description 24
239000000427 antigen Substances 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
230000003993 interaction Effects 0.000 description 24
230000006698 induction Effects 0.000 description 23
238000012545 processing Methods 0.000 description 23
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
108091028043 Nucleic acid sequence Proteins 0.000 description 21
230000003367 anti-collagen effect Effects 0.000 description 20
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 20
238000000099 in vitro assay Methods 0.000 description 19
239000003446 ligand Substances 0.000 description 19
238000002054 transplantation Methods 0.000 description 19
206010061218 Inflammation Diseases 0.000 description 18
230000008901 benefit Effects 0.000 description 18
230000015572 biosynthetic process Effects 0.000 description 18
230000004054 inflammatory process Effects 0.000 description 18
239000011159 matrix material Substances 0.000 description 18
229960005347 belatacept Drugs 0.000 description 17
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 17
230000004044 response Effects 0.000 description 17
108060003951 Immunoglobulin Proteins 0.000 description 16
230000014509 gene expression Effects 0.000 description 16
102000018358 immunoglobulin Human genes 0.000 description 16
238000003786 synthesis reaction Methods 0.000 description 16
108020004705 Codon Proteins 0.000 description 15
102000004127 Cytokines Human genes 0.000 description 15
108090000695 Cytokines Proteins 0.000 description 15
102220502536 Platelet-activating factor acetylhydrolase IB subunit alpha2_G55E_mutation Human genes 0.000 description 15
210000004899 c-terminal region Anatomy 0.000 description 15
230000006870 function Effects 0.000 description 15
-1 multimer Proteins 0.000 description 15
102220252247 rs1555583645 Human genes 0.000 description 15
230000016396 cytokine production Effects 0.000 description 14
230000002163 immunogen Effects 0.000 description 14
102220222791 rs1060501227 Human genes 0.000 description 14
102220082934 rs201875716 Human genes 0.000 description 14
230000028327 secretion Effects 0.000 description 14
230000009286 beneficial effect Effects 0.000 description 13
238000005462 in vivo assay Methods 0.000 description 13
230000002757 inflammatory effect Effects 0.000 description 13
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 13
230000011664 signaling Effects 0.000 description 13
230000000295 complement effect Effects 0.000 description 12
229920000642 polymer Polymers 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 12
108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
108010002350 Interleukin-2 Proteins 0.000 description 11
102000000588 Interleukin-2 Human genes 0.000 description 11
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
239000004472 Lysine Substances 0.000 description 11
108060008682 Tumor Necrosis Factor Proteins 0.000 description 11
238000004458 analytical method Methods 0.000 description 11
238000010494 dissociation reaction Methods 0.000 description 11
230000005593 dissociations Effects 0.000 description 11
230000007170 pathology Effects 0.000 description 11
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 11
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 10
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 10
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 10
108010038453 Interleukin-2 Receptors Proteins 0.000 description 10
102000010789 Interleukin-2 Receptors Human genes 0.000 description 10
230000005875 antibody response Effects 0.000 description 10
238000012217 deletion Methods 0.000 description 10
230000037430 deletion Effects 0.000 description 10
238000002650 immunosuppressive therapy Methods 0.000 description 10
230000001976 improved effect Effects 0.000 description 10
102220232156 rs370120266 Human genes 0.000 description 10
102200027760 rs75193786 Human genes 0.000 description 10
241000894007 species Species 0.000 description 10
208000024891 symptom Diseases 0.000 description 10
238000012360 testing method Methods 0.000 description 10
108010047041 Complementarity Determining Regions Proteins 0.000 description 9
108010087819 Fc receptors Proteins 0.000 description 9
102000009109 Fc receptors Human genes 0.000 description 9
102100040247 Tumor necrosis factor Human genes 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
230000001086 cytosolic effect Effects 0.000 description 9
239000012636 effector Substances 0.000 description 9
XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
206010039073 rheumatoid arthritis Diseases 0.000 description 9
238000002864 sequence alignment Methods 0.000 description 9
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 9
206010062016 Immunosuppression Diseases 0.000 description 8
238000007792 addition Methods 0.000 description 8
238000003556 assay Methods 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000016784 immunoglobulin production Effects 0.000 description 8
238000004364 calculation method Methods 0.000 description 7
210000000987 immune system Anatomy 0.000 description 7
239000000047 product Substances 0.000 description 7
230000035755 proliferation Effects 0.000 description 7
238000012216 screening Methods 0.000 description 7
108091026890 Coding region Proteins 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
108020004511 Recombinant DNA Proteins 0.000 description 6
102220550784 Unconventional myosin-X_V32I_mutation Human genes 0.000 description 6
210000000612 antigen-presenting cell Anatomy 0.000 description 6
239000003085 diluting agent Substances 0.000 description 6
239000013604 expression vector Substances 0.000 description 6
238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 6
230000000670 limiting effect Effects 0.000 description 6
229930182817 methionine Natural products 0.000 description 6
230000035772 mutation Effects 0.000 description 6
208000002193 Pain Diseases 0.000 description 5
230000005867 T cell response Effects 0.000 description 5
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 5
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 5
230000004940 costimulation Effects 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
238000010586 diagram Methods 0.000 description 5
230000000694 effects Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
230000009870 specific binding Effects 0.000 description 5
206010063836 Atrioventricular septal defect Diseases 0.000 description 4
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
241001529936 Murinae Species 0.000 description 4
108091008874 T cell receptors Proteins 0.000 description 4
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
239000003623 enhancer Substances 0.000 description 4
230000002519 immonomodulatory effect Effects 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
238000003780 insertion Methods 0.000 description 4
230000037431 insertion Effects 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
102200128633 rs104893843 Human genes 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
239000000126 substance Substances 0.000 description 4
238000013518 transcription Methods 0.000 description 4
230000035897 transcription Effects 0.000 description 4
108010074051 C-Reactive Protein Proteins 0.000 description 3
102100032752 C-reactive protein Human genes 0.000 description 3
108091006020 Fc-tagged proteins Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical group OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
229960003697 abatacept Drugs 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
230000000139 costimulatory effect Effects 0.000 description 3
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000000899 immune system response Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
239000003018 immunosuppressive agent Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
230000000750 progressive effect Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
102200163548 rs63751094 Human genes 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
208000006820 Arthralgia Diseases 0.000 description 2
102000005738 B7 Antigens Human genes 0.000 description 2
108010045634 B7 Antigens Proteins 0.000 description 2
102220573534 C-C motif chemokine 5_G55K_mutation Human genes 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004635 Complementary DNA Proteins 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
241000283073 Equus caballus Species 0.000 description 2
108091029865 Exogenous DNA Proteins 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000282575 Gorilla Species 0.000 description 2
102000009490 IgG Receptors Human genes 0.000 description 2
108010073807 IgG Receptors Proteins 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
206010023232 Joint swelling Diseases 0.000 description 2
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
241000009328 Perro Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
208000025747 Rheumatic disease Diseases 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
230000002950 deficient Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000001211 electron capture detection Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
239000000710 homodimer Substances 0.000 description 2
230000008004 immune attack Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229940047124 interferons Drugs 0.000 description 2
238000000111 isothermal titration calorimetry Methods 0.000 description 2
239000003550 marker Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
238000002823 phage display Methods 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
238000003259 recombinant expression Methods 0.000 description 2
102220277465 rs1403203490 Human genes 0.000 description 2
102220029635 rs146867923 Human genes 0.000 description 2
230000007017 scission Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
230000001629 suppression Effects 0.000 description 2
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
230000005030 transcription termination Effects 0.000 description 2
230000014616 translation Effects 0.000 description 2
238000013519 translation Methods 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
238000012800 visualization Methods 0.000 description 2
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
101100235064 Arabidopsis thaliana LEA29 gene Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
230000003844 B-cell-activation Effects 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
238000012492 Biacore method Methods 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000841411 Homo sapiens Protein ecdysoneless homolog Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
241001527806 Iti Species 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
108060001084 Luciferase Proteins 0.000 description 1
239000005089 Luciferase Substances 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
241000282405 Pongo abelii Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102220493431 Putative uncharacterized protein encoded by MIR7-3HG_K28N_mutation Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
230000017274 T cell anergy Effects 0.000 description 1
102000009618 Transforming Growth Factors Human genes 0.000 description 1
108010009583 Transforming Growth Factors Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
238000000246 agarose gel electrophoresis Methods 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
238000003277 amino acid sequence analysis Methods 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000010367 cloning Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000007402 cytotoxic response Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000005547 deoxyribonucleotide Substances 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
239000000428 dust Substances 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000019688 fish Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
150000002337 glycosamines Chemical group 0.000 description 1
239000005090 green fluorescent protein Substances 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012615 high-resolution technique Methods 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
102000047791 human ECD Human genes 0.000 description 1
230000008348 humoral response Effects 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000003259 immunoinhibitory effect Effects 0.000 description 1
210000000428 immunological synapse Anatomy 0.000 description 1
230000020287 immunological synapse formation Effects 0.000 description 1
239000002955 immunomodulating agent Substances 0.000 description 1
229940121354 immunomodulator Drugs 0.000 description 1
230000002584 immunomodulator Effects 0.000 description 1
208000025095 immunoproliferative disease Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
229940125721 immunosuppressive agent Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000001503 joint Anatomy 0.000 description 1
208000018937 joint inflammation Diseases 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000009149 molecular binding Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
238000001216 nucleic acid method Methods 0.000 description 1
238000001668 nucleic acid synthesis Methods 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
238000005457 optimization Methods 0.000 description 1
101710135378 pH 6 antigen Proteins 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000008488 polyadenylation Effects 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001124 posttranscriptional effect Effects 0.000 description 1
230000036515 potency Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000012121 regulation of immune response Effects 0.000 description 1
230000032537 response to toxin Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
102220065537 rs201161721 Human genes 0.000 description 1
102220044848 rs377730553 Human genes 0.000 description 1
102220321637 rs377730553 Human genes 0.000 description 1
102220059216 rs771261665 Human genes 0.000 description 1
102220241278 rs777474053 Human genes 0.000 description 1
102220000564 rs78778622 Human genes 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
230000037432 silent mutation Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1

Landscapes

Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

CA2805976A 2007-11-01 2008-10-15 Polypeptide immunosuppresseur et acides nucleiques Expired - Fee Related CA2805976C (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US98463107P	2007-11-01	2007-11-01
US60/984,631		2007-11-01
US5121508P	2008-05-07	2008-05-07
US61/051,215		2008-05-07
CA2703263A CA2703263C (fr)	2007-11-01	2008-10-15	Polypeptide immunosuppresseur et acides nucleiques

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2703263A Division CA2703263C (fr)	2007-11-01	2008-10-15	Polypeptide immunosuppresseur et acides nucleiques

Publications (2)

Publication Number	Publication Date
CA2805976A1 CA2805976A1 (fr)	2009-05-07
CA2805976C true CA2805976C (fr)	2015-05-26

Family

ID=47833546

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2805976A Expired - Fee Related CA2805976C (fr)	2007-11-01	2008-10-15	Polypeptide immunosuppresseur et acides nucleiques

Country Status (2)

Country	Link
CA (1)	CA2805976C (fr)
SI (1)	SI2222697T1 (fr)

2008
- 2008-10-15 CA CA2805976A patent/CA2805976C/fr not_active Expired - Fee Related
- 2008-10-15 SI SI200830874T patent/SI2222697T1/sl unknown

Also Published As

Publication number	Publication date
SI2222697T1 (sl)	2013-03-29
CA2805976A1 (fr)	2009-05-07

Legal Events

Date	Code	Title	Description
2013-03-06	EEER	Examination request	Effective date: 20130206
2013-03-15	EEER	Examination request	Effective date: 20130206
2019-11-26	MKLA	Lapsed	Effective date: 20191015

Publication	Publication Date	Title
AU2008319053B2 (en)	2012-04-26	Immunosuppressive polypeptides and nucleic acids
KR101378194B1 (ko)	2014-03-27	안정한 단백질 제제
CA2805976C (fr)	2015-05-26	Polypeptide immunosuppresseur et acides nucleiques
AU2014250683B2 (en)	2015-11-26	Immunosuppressive polypeptides and nucleic acids
AU2012202324B2 (en)	2014-08-28	Immunosuppressive polypeptides and nucleic acids